Last reviewed · How we verify
PARP Inhibitor BGB-290
At a glance
| Generic name | PARP Inhibitor BGB-290 |
|---|---|
| Also known as | BGB-290, PARP, Inhibitor BGB-290, BGB-290, Pamiparib |
| Sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Fatigue
- Lymphocyte count decreased
- Neutrophil count decreased
- White blood cell decreased
- Gastroesophageal Acid Reflux
- anemia
- Nausea
- Hypophosphatemia
- Platelet count decreased
- Weight loss
- Alanine aminotransferase increase
- Anorexia
Key clinical trials
- Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (PHASE3)
- Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer (PHASE3)
- BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas (PHASE1)
- Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer (PHASE1)
- Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors (PHASE1)
- A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma (PHASE1, PHASE2)
- Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors (PHASE1, PHASE2)
- BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: